Drug resistance arises when organisms that are targeted by drugs evolve ways to survive treatment. It is a major challenge in treating bacterial infections, viral diseases, cancers and parasitic infections.

In bacteria, resistance can result from gene mutations or from acquiring resistance genes from other microbes. These changes can alter drug targets, increase drug efflux, or produce enzymes that break down antibiotics. Misuse and overuse of antibiotics in medicine and agriculture accelerate the spread of resistant strains. This leads to infections that are harder, slower and more expensive to treat.

Viruses, such as HIV and influenza, develop resistance particularly quickly because they mutate rapidly and often replicate with low fidelity. Antiviral resistance can emerge against drugs that target viral enzymes or entry pathways. Combination therapies and careful treatment monitoring help delay resistance.

In cancer, drug resistance can be intrinsic or acquired during therapy. Tumor cells may increase drug efflux, repair drug induced DNA damage more efficiently, activate alternative signaling pathways, or exist in protected microenvironments. Tumor heterogeneity means some cells can survive treatment and repopulate the cancer.

Parasitic organisms, including malaria parasites and worms, also evolve resistance to antiparasitic drugs via target changes, altered metabolism or decreased drug uptake.

Combating drug resistance involves using drugs more judiciously, developing diagnostics that guide targeted therapy, combining drugs that act on different targets, and designing new molecules that evade known resistance mechanisms. Surveillance, global coordination and ongoing basic research into evolutionary and molecular mechanisms are essential to preserve the effectiveness of existing and future treatments.